Crit-Line In-Line Monitor
This policy describes Aetna's coverage stance for the Crit-Line in-line monitor used to measure hematocrit and oxygen saturation during hemodialysis and which members/providers it affects.
No material clinical or coverage changes in this revision.
Coverage Determination
Not established as medically necessary / investigational
Aetna's coverage conclusion for the Crit-Line In-Line Monitor
Statement of noncoverage stance based on insufficient evidence.
Use of the Crit-Line In‑Line Monitor for monitoring hematocrit and oxygen saturation is considered experimental and investigational and is excluded from coverage under this policy.
The device is considered investigational because the effectiveness of the Crit‑Line In‑Line Monitor in avoiding intra‑dialytic morbid events, in preventing ischemia due to intra‑dialytic hypoxia, and in determining access re‑circulations has not been demonstrated. Clinical reports (for example Steuer et al.) have evaluated blood‑volume monitoring and tolerance of additional fluid removal but do not establish that use of the Crit‑Line reduces intradialytic morbidity or prevents ischemic events.
Coding and Billing
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.